Loading...
Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
Tumor-associated macrophage (TAM) significantly contributes to cancer progression. Human cancer is enhanced by PPARγ loss-of-function mutations, but inhibited by PPARγ agonists such as TZD diabetes drugs including rosiglitazone. However, it remains enigmatic whether and how macrophage contributes to...
Na minha lista:
| Udgivet i: | eLife |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
eLife Sciences Publications, Ltd
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5047746/ https://ncbi.nlm.nih.gov/pubmed/27692066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.18501 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|